TY - JOUR
T1 - Budget impact analysis of pneumococcal conjugate vaccines in Colombia
AU - Gomez, Jorge
AU - Moreno, Luz Elena
AU - Constenla, Dagna
AU - Caceres, Diana
AU - Rodriguez, Edisson
N1 - Funding Information:
GlaxoSmithKline Biologicals SA (HO-19-20065) funded all costs associated with the development of this publication. The authors thank Business & Decision Life Sciences platform (on behalf of GSK) for editorial assistance, manuscript coordination and writing support. Pierre-Paul Prevot coordinated the manuscript development and editorial support. Carole Nadin (Fleetwith Ltd, on behalf of GSK) provided editorial support.
Publisher Copyright:
© 2020 GlaxoSmithKline Biologicals S.A., Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2021
Y1 - 2021
N2 - Objective: Pneumococcal diseases including invasive pneumococcal disease (IPD), pneumonia, and acute otitis media (AOM) impose a substantial public health burden. This study performed a budget impact analysis of the use of pneumococcal conjugate vaccines (PCVs) in the National Immunization Program (NIP) in Colombia. Methods: We compared the direct medical cost of the scenario without and with PCV vaccination using either pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) or 13-valent pneumococcal conjugate vaccine (PCV-13) over 5 years (2020–2024) from the health-care system perspective. Vaccine efficacy estimates were obtained from published sources and vaccine prices were taken from the Pan-American Health Organization Revolving Fund. Vaccine coverage was assumed to be 90% based on Colombia data. Results: Using PHiD-CV in the NIP in Colombia would reduce the estimated cost for treating pneumococcal disease by US$46.1 m over the 2020–2024 period (US$40.2 m using PCV-13), with a budget impact of US$100.1 m for PHiD-CV (US$121.4 m for PCV-13), and would cost US$3.1 m less per year on vaccine doses than using PCV-13. Conclusion: These findings are potentially valuable for the selection of vaccines for their national immunization programs under conditions of budgetary constraint.
AB - Objective: Pneumococcal diseases including invasive pneumococcal disease (IPD), pneumonia, and acute otitis media (AOM) impose a substantial public health burden. This study performed a budget impact analysis of the use of pneumococcal conjugate vaccines (PCVs) in the National Immunization Program (NIP) in Colombia. Methods: We compared the direct medical cost of the scenario without and with PCV vaccination using either pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) or 13-valent pneumococcal conjugate vaccine (PCV-13) over 5 years (2020–2024) from the health-care system perspective. Vaccine efficacy estimates were obtained from published sources and vaccine prices were taken from the Pan-American Health Organization Revolving Fund. Vaccine coverage was assumed to be 90% based on Colombia data. Results: Using PHiD-CV in the NIP in Colombia would reduce the estimated cost for treating pneumococcal disease by US$46.1 m over the 2020–2024 period (US$40.2 m using PCV-13), with a budget impact of US$100.1 m for PHiD-CV (US$121.4 m for PCV-13), and would cost US$3.1 m less per year on vaccine doses than using PCV-13. Conclusion: These findings are potentially valuable for the selection of vaccines for their national immunization programs under conditions of budgetary constraint.
KW - 13-valent pneumococcal conjugate vaccine
KW - Budget impact analysis
KW - colombia
KW - pneumococcal conjugate vaccination
KW - pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine
UR - http://www.scopus.com/inward/record.url?scp=85097367598&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85097367598&partnerID=8YFLogxK
U2 - 10.1080/14737167.2021.1855978
DO - 10.1080/14737167.2021.1855978
M3 - Article
C2 - 33249948
AN - SCOPUS:85097367598
SN - 1473-7167
VL - 21
SP - 255
EP - 263
JO - Expert Review of Pharmacoeconomics and Outcomes Research
JF - Expert Review of Pharmacoeconomics and Outcomes Research
IS - 2
ER -